Article
Immunology
Paolo F. Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, Folashade Otegbeye, Nausheen Ahmed, Patricio Rojas, Seema Patel, Sarah Kleinsorge Block, Jennifer Schiavone, Kayla Zamborsky, Kirsten Boughan, Antoinette Hillian, Jane Reese-Koc, Mikhail Maschan, Boro Dropulic, Rafick-Pierre Sekaly, Marcos De Lima
Summary: In this study, the efficacy of anti-CD19 CAR-T cells in treating relapsed/refractory lymphoma patients was investigated. Prophylactic use of tocilizumab was found to reduce the incidence and severity of cytokine release syndrome, without increasing the frequency or severity of ICANS, leading to improved treatment outcomes and survival rates for patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Hematology
Tomohiro Aoki, Christian Steidl
Summary: The emergence and rapid development of single-cell technologies have transformed cancer research, providing powerful tools to understand cellular heterogeneity and interactions at the single-cell level. Recent advances in single-cell RNA sequencing have improved our understanding of lymphoma, particularly classical Hodgkin lymphoma (CHL), by revealing heterogeneity in malignant cell differentiation states and the composition of the tumor microenvironment (TME). These technologies hold promise for biomarker discovery and immunotherapeutic development for lymphoma treatment.
Article
Oncology
Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt
Summary: CAR-T cell therapy is effective in treating relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) patients, but infections resulting from lymphodepletion or CAR-T cell therapy can lead to severe and potentially life-threatening complications. Identification and treatment of infections are crucial in these immunocompromised patients, with standardized prophylaxis and supportive therapy being necessary to reduce morbidity and mortality. Infections are common in CAR-T cell treated patients, but overall serious complications are rare, highlighting the importance of fast and appropriate management in this vulnerable patient population.
Review
Oncology
Zixun Yin, Ya Zhang, Xin Wang
Summary: B-cell non-Hodgkin lymphoma is a heterogeneous disease that remains incurable, necessitating the development of novel therapies. CAR-T cell therapy shows promising potential in refractory or relapsed B-NHL, but comes with adverse effects. New antigen-targeted CAR-T products and four-generation CAR-T are rapidly developing to overcome these limitations.
BIOMARKER RESEARCH
(2021)
Article
Cell Biology
Julia Bein, Nadine Flinner, Bjorn Haeupl, Aastha Mathur, Olga Schneider, Marwa Abu-Ayyad, Martin-Leo Hansmann, Matthieu Piel, Thomas Oellerich, Sylvia Hartmann
Summary: Based on proteomics and migration behavior, T-cell-derived cHL is a neoplasm that shares features with both cHL and ALCL, and is not an ALCL with low tumor cell content. Complementary clinical studies on this lymphoma are warranted.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Review
Hematology
Carrie Ho, Marco Ruella, Bruce L. Levine, Jakub Svoboda
Summary: Although CAR T-cell therapy has been approved for B-cell non-Hodgkin lymphomas, the progress for classic Hodgkin lymphoma (cHL) has been slower. Early clinical trials have shown promising clinical responses with the use of Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells in cHL patients, and research on CD19 and CD123 CAR T cells targeting the immunosuppressive tumor microenvironment in cHL is ongoing.
Article
Oncology
Yutao Li, Amit Sharma, Maurits Bloemendal, Roland Schmidt-Wolf, Miroslaw Kornek, Ingo Schmidt-Wolf
Summary: CIK cells have cytotoxic effects on B-NHL cells, and a combination therapy of PD-1 inhibitors with CIK cells may offer a potential treatment option for this type of lymphoma. Further in vivo experiments are needed to determine the extent of enhancement of antitumor activity in B-NHL by PD-1 inhibitors.
Article
Dentistry, Oral Surgery & Medicine
S. Leng, W. Xu, L. Wu, L. Liu, J. Du, F. Yang, D. Huang, L. Zhang
Summary: Apical periodontitis is an inflammatory condition caused by immunological reaction to invading bacteria. NLRP3 plays a crucial role in the pathogenesis of this condition by disturbing the balance between Treg and Th17 cells. The dysregulation of NLRP3 exacerbates periapical inflammation and bone resorption.
JOURNAL OF DENTAL RESEARCH
(2023)
Article
Hematology
Maria Gluud, Emil M. H. Pallesen, Terkild B. Buus, Lise Mette Rahbek Gjerdrum, Lise M. Lindahl, Maria R. Kamstrup, Michael Bzorek, Maria Danielsen, Rikke Bech, Madalena N. Monteiro, Edda Blumel, Andreas Willerslev-Olsen, Anders Lykkebo-Valloe, Chella Krishna Vadivel, Thorbjorn Krejsgaard, Charlotte Menne Bonefeld, Carsten Geisler, Juergen C. Becker, Sergei B. Koralov, Lars Iversen, Thomas Litman, Anders Woetmann, Niels Odum
Summary: Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms and increase the risk of bacterial infection. The study found that malignant T cells secrete cytokines that downregulate the expression of filaggrin and filaggrin-2, leading to compromised skin barrier. Treatment with JAK inhibitors can reverse this effect and increase filaggrin expression in patients with advanced CTCL.
Article
Health Care Sciences & Services
Jeremy A. Meier, Barbara Savoldo, Natalie S. Grover
Summary: Treatment for Hodgkin lymphoma has advanced significantly, but a portion of patients still experience relapse or disease progression. Immunotherapies, particularly CAR T cells, have shown exceptional promise in treating relapsed/refractory HL.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Article
Hematology
Kennosuke Karube, Mitsuyoshi Takatori, Shugo Sakihama, Yuma Tsuruta, Takashi Miyagi, Kazuho Morichika, Sakiko Kitamura, Norihiro Nakada, Masaki Hayashi, Shohei Tomori, Iwao Nakazato, Kazuiku Ohshiro, Naoki Imaizumi, Yara Yukie Kikuti, Naoya Nakamura, Satoko Morishima, Hiroaki Masuzaki, Takuya Fukushima
Summary: This study describes the characteristics of HTLV-1-infected HRS-like cells in patients with ATLL, showing differences from classic CHL, mainly characterized by HBZ-ISH positivity and negativity for PAX5 and EBV.
Article
Cell Biology
Frank Cichocki, Bin Bin Zhang, Cheng-Ying Wu, Emily Chiu, Abderrahman Day, Roddy S. O'Connor, Dima Yackoubov, Ronit Simantov, David H. McKenna, Qing Cao, Todd E. Defor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Nathaniel Snyder, Akhilesh Kumar, Bartosz Grzywacz, Justin Hwang, Yona Geffen, Jeffrey S. Miller, Joseph Maakaron, Veronika Bachanova
Summary: Allogeneic natural killer (NK) cell adoptive transfer, enhanced by ex vivo culture with interleukin-15 (IL-15) and nicotinamide (NAM), leads to stable induction of l-selectin (CD62L), and metabolic changes associated with elevated glucose flux. This approach improves NK cell survival, function, and persistence, and shows promising results in a clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The therapy, named GDA-201, demonstrates high tolerability, favorable metabolic profile, and an overall response rate of 74% in advanced NHL patients.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Letter
Immunology
Janina Trauth, Thomas Discher, Moritz Fritzenwanker, Can Imirzalioglu, Tobias Arnold, Dagmar Steiner, Elvira Richter, Laura Crisponi, Bodo Grimbacher, Susanne Herold
Summary: Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, usually occurs in heavily immunocompromised patients. We report a case of disseminated M. genavense infection preceding Hodgkin lymphoma in a patient without obvious risk factors for this infection.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Adam Ustaszewski, Julia Paczkowska, Joanna Janiszewska, Stephan H. Bernhart, Julia Bein, Nuria Russinol, Martin-Leo Hansmann, Vicente Chapaprieta, Jose I. Martin-Subero, Reiner Siebert, Sylvia Hartmann, Maciej Giefing
Summary: This study identified potential novel oncomiRs in classic Hodgkin Lymphoma (cHL) cell lines, including two miRNAs expressed together with the TENM2 gene. The open chromatin and hypomethylation of TENM2 gene in cHL cell lines suggest an epigenetic mechanism for the aberrant expression of both the TENM2 gene and the novel miRNA. Although no typical cHL-related ontologies were found, several interesting candidate genes involved in lymphopoiesis were identified.
